A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma
Latest Information Update: 27 Oct 2020
At a glance
- Drugs SGN 30 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 25 May 2011 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 25 May 2011 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 19 Dec 2006 Status change from in progress to completed